, 37:270 | Cite as

Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy

  • A. Antinori
  • A. Ammassari
  • C. Torti
  • P. Marconi
  • M. Andreoni
  • G. Angarano
  • S. Bonora
  • A. Castagna
  • R. Cauda
  • M. Clerici
  • A. d’Arminio Monforte
  • A. De Luca
  • G. Di Perri
  • M. Galli
  • E. Girardi
  • A. Gori
  • A. Lazzarin
  • S. Lo Caputo
  • F. Mazzotta
  • F. Montella
  • C. Mussini
  • C. F Perno
  • M. Puoti
  • G. Rizzardini
  • S. Rusconi
  • V. Vullo
  • G. Carosi
Consensus Report



Individuals with advanced HIV infection naïve to antiretroviral therapy represent a special population of patients frequently encountered in clinical practice. They are at high risk of disease progression and death, and their viroimmunologic response following the initiation of highly active antiretroviral therapy may be more incomplete or slower than that of other patients. Infection management in such patients can also be complicated by underlying conditions, comorbidities, and the need for concomitant medications.


To provide practical guidelines to those clinicians providing care to HIV-infected patients in terms of diagnostic assessment, monitoring, and treatment.


The principals of antiretroviral treatment in asymptomatic naïve patients with advanced HIV infection are the same as those applicable to the general population with asymptomatic HIV infection. Naïve patients with advanced HIV infection and a history of AIDS-defining illnesses urgently need antiretroviral treatment, with the choice of antiretroviral regimen and timetable based on such factors as concomitant treatment and prophylaxis, drug interactions, and potential concomitant drug toxicity. Finally, an adequate counseling program – both before and after HIV-testing – that includes aspects other than treatment adherence monitoring is a crucial step in disease management.


  1. 1.
    Schwarcz S, Hsu L, Dilley JW, Loeb L, Nelson K, Boyd S: Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J Acquir Immune Defic Syndr 2006; 43: 491–494.PubMedCrossRefGoogle Scholar
  2. 2.
    Girardi E, Sabin CA, Monforte AD: Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46: S3–S8.PubMedCrossRefGoogle Scholar
  3. 3.
    Battegay M, Fluckiger U, Hirschel B, Furrer H: Late presentation of HIV-infected individuals. Antivir Ther 2007; 12: 841–851.PubMedGoogle Scholar
  4. 4.
    Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS: Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy? J Acquir Immune Defic Syndr 2005; 38: 289–295.PubMedGoogle Scholar
  5. 5.
    Sabin CA, Smith CJ, Youle M, Lampe FC, Bell DR, Puradiredja D, Lipman MC, Bhagani S, Phillips AN, Johnson MA: Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006; 20: 67–71.PubMedCrossRefGoogle Scholar
  6. 6.
    Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, Panos G, Mercey D, Machala L, Horban A, Lundgren JD, EuroSIDA study group: Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis 2004; 190: 148–155.PubMedCrossRefGoogle Scholar
  7. 7.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study: Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41: 361–372.PubMedCrossRefGoogle Scholar
  8. 8.
    Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D’Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME, Antiretroviral Therapy Cohort Collaboration: Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362: 679–686.PubMedCrossRefGoogle Scholar
  9. 9.
    Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD, HIV Outpatient Study Investigators: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138: 620–626.PubMedGoogle Scholar
  10. 10.
    Panel on antiretroviral guidelines for adults and adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 29 January 2008; pp 1–128. Available at: Accessed: 16 July 2008.
  11. 11.
    Centers for Disease Control and Prevention: Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR recommendations and reports. December 18, 1992/41 (RR-17).Google Scholar
  12. 12.
    Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, HIV Outpatient Study Investigators: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Phillips AN, Lundgren JD: The CD4 lymphocyte count and risk of clinical progression. Curr Opin HIV AIDS 2006; 1: 43–49.PubMedCrossRefGoogle Scholar
  14. 14.
    Nunn P, Brindle R, Carpenter L, Odhiambo J, Wasunna K, Newnham R, Githui W, Gathua S, Omwega M, McAdam K: Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis 1992; 146: 849–854.PubMedGoogle Scholar
  15. 15.
    Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA: Should resistance testing be performed for treatment-naïve HIV-infected patients? A costeffectiveness analysis. Clin Infect Dis 2005; 41: 1316–1323.PubMedCrossRefGoogle Scholar
  16. 16.
    Palmer S, Boltz V, Maldarelli F, Halvas E, Mellors J, Coffin J: New real-time PCR assay quantifies K103N NNRTI-resistant variant at a frequency as lowas 0.01%[abstract P36]. In: Programand abstracts of the National Cancer Institute third HIV drug resistance program symposium: antiviral drug resistance (Chantilly,VA, 8-11December 2002). National Cancer Institute, Bethesda 2002, pp 74.Google Scholar
  17. 17.
    Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191: 866–872.PubMedCrossRefGoogle Scholar
  18. 18.
    Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, PREDICT-1 Study Team: HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568–579.PubMedCrossRefGoogle Scholar
  19. 19.
    Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK, CDC, National Institutes of Health; Infectious Diseases Society of America. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/InfectiousDiseases Society of America. MMWR Recomm Rep 17 Dec 2004; 53(RR-15): 1–112.Google Scholar
  20. 20.
    Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P: Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006; 7: 56.PubMedCrossRefGoogle Scholar
  21. 21.
    Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB, ACTG 384 Team: Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42: 426–434.PubMedCrossRefGoogle Scholar
  22. 22.
    Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ: Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42: 1639–1646.PubMedCrossRefGoogle Scholar
  23. 23.
    French MA, Price P, Stone SF: Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615–1627.PubMedCrossRefGoogle Scholar
  24. 24.
    Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A: AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282: 2220–2226.PubMedCrossRefGoogle Scholar
  25. 25.
    Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M, CASCADE Collaboration: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20: 741–749.PubMedGoogle Scholar
  26. 26.
    Jaen A, Esteve A, Montoliu A, Miro J, Podzamczer D, Tural C, Riera M, Segura F, Force L, Vilaro L, Garcia I, Masabeu A, Altes J, Sued O, Clotet B, Ferrer E, Casabona J, Piscis Study Group: When is the optimal moment to start HAART in HIV infected patients from PISCIS cohort study (Spain)? Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27–30 September 2006; San Francisco, California. Abstract H-1059.Google Scholar
  27. 27.
    d’Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M, The Antiretroviral Therapy Cohort Collaboration: The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165: 416–423.PubMedCrossRefGoogle Scholar
  28. 28.
    Carosi G, Quiros-Roldan E, Torti C, Antinori A, Bevilacqua M, Bonadonna RC, Bonfanti P, Castagna A, Cauda R, d’Arminio-Monforte A, Di Gregorio P, Di Perri G, Esposito R, Fatuzzo F, Gervasoni C, Giannatasio C, Guaraldi G, Lazzarin A, Lo Caputo S, Maggi P, Mazzotta F, Moroni M, Prestileo T, Ranieri R, Rizzardini G, Russo R, Galli M, members of the Italian Cardiovascular Risk Guidelines Working Group: First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIVinfected patients in the ERA (2006). Infection 2007; 35: 1–9.CrossRefGoogle Scholar
  29. 29.
    Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormaasen V, Gargalianos-Kakolyris P, Vella S, Lundgren JD: Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186: 189–197.PubMedCrossRefGoogle Scholar
  30. 30.
    Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS: Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence. AIDS 2004; 18: 2432–2434.PubMedGoogle Scholar
  31. 31.
    MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Kozal MJ, van den Berg-Wolf M, Henely C, Huppler-Hullsiek K, Schmetter B, Dehlinger M, for the CPCRA 058 Study Team and the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA): Long-term clinical and immunologic outcomes are similar in HIV-infected persons randomized to NNRTI vs PI vs NNRTI + PI-based antiretroviral regimens as initial therapy: results of the CPCRA 058 FIRST study. Program and abstracts of the XVI International AIDS Conference; 13–18 August 2006, Toronto, Canada. Abstract TUAB0102.Google Scholar
  32. 32.
    Pulido F, Arribas JR, Miro JM, Costa MA, Gonzalez J, Rubio R, Pena JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vazquez JJ, Gatell JM, EfaVIP Cohort Study Group: Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviralnaïve patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr 2004; 35: 343–350.PubMedCrossRefGoogle Scholar
  33. 33.
    Riddler SA, Haubrich R, DiRienzo G, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Havlir D, Mellors JW, AIDS Clinical Trials Group 5142 Study Team: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. Program and abstracts of the XVI International AIDS Conference; 13–18 August 2006, Toronto, Canada. Abstract THLB0204.Google Scholar
  34. 34.
    Barreiro P, Soriano V, Casas E, Gonzalez-Lahoz J: Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002; 16: 245–249.PubMedCrossRefGoogle Scholar
  35. 35.
    Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Moller N, Weber J, Horban A, Staszewski S, Lundgren JD, Phillips AN, EuroSIDA Study Group: Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19: 319–330.PubMedGoogle Scholar
  36. 36.
    Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, Benson C, King KR, Murphy RL, Brun SC: Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatmentnaïve patients: 4 year follow-up study. AIDS 2004; 18: 775–779.PubMedCrossRefGoogle Scholar
  37. 37.
    Murphy R, da Silva B, McMillan F, Hicks C, Eron J, Wolfe P, Gulick R, Glesby M, Thompson M, Benson C, White AC, Albrecht M, Kessler H, Niemi K, King K, Calhoun D, King M, Hanna G, Brun S: Seven year follow-up of a lopinavir/ritonavir-based regimen in antiretroviral-naïve subjects. In: 10th European AIDS Conference. 17–20 November 2005. Dublin. Abstract PE7.9/3.Google Scholar
  38. 38.
    Eron J, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, Lackey P, Yau L, Sutherland-Phillips D, Wannamaker P, Shaefer M: The KLEAN study: fosamprenavir + ritonavir (FPV/r) versus lopinavir/ritonavir (LPV/r) in antiretroviral-naïve (ART naïve) HIV-1 infected adults over 48 weeks. Program and abstracts of the XVI International AIDS Conference, 13–18 August 2006, Toronto, Canada. Abstract THLB0205.Google Scholar
  39. 39.
    Smith K, Weinberg W, DeJesus E, et al. Efficacy and safety of once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral-naïve HIV-infected patients: 24-week results from COL103952 (ALERT). Program and abstracts of the 46th interscience conference on antimicrobial agents and chemotherapy, 27–30 September 2006, San Francisco, CA. Abstract H-1670a.Google Scholar
  40. 40.
    Clumeck N, Van Lunzen J, Chiliade P, Clotet B, Vanden Abeele C, Lefebvre E, Vangeneugden T, Spinosa-Guzman S, DeMasi R: ARTEMIS — Efficacy and Safety of Lopinavir (BID vs QD) and Darunavir (QD) in Antiretroviral-naïve Patients. In: 11th European AIDS Conference, Madrid, 2007. Abstract LBPS7/5.Google Scholar
  41. 41.
    Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR, AIDS Clinical Trials Group (ACTG) A5095 Study Team: Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296: 769–781.PubMedCrossRefGoogle Scholar
  42. 42.
    Delfraissy JF, Flandre P, Delaugerre C, Horban A, Girard PM, Rouzioux C, Norton M, Cohen-Codar I, NgoVan P, Chauvin JP: 48 Week analysis of LPV/r monotherpay compared to LPV/r + AZT/3TC in antiretroviral- naïve patients: MONARK trial. XVI International AIDS Conference, 13–18 Aug 2006, Toronto, Canada. Abstract THLB0202.Google Scholar
  43. 43.
    Boyd MA, Dixit NM, Siangphoe U, Buss NE, Salgo MP, Lange JM, Phanuphak P, Cooper DA, Perelson AS, Ruxrungtham K: Viral decay dynamics in HIV-infected patients receiving ritonavirboosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). J Infect Dis 2006; 194: 1319–1322.PubMedCrossRefGoogle Scholar
  44. 44.
    Antinori A, Cozzi-Lepri A, Ammassari A, Trotta MP, Nauwelaers D, Hoetelmans R, Murri R, Melzi S, Narciso P, Nasta P, Zaccarelli M, Santopadre P, Vecchiet J, Izzo CM, Monforte A, AdICoNA Study Group: Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther 2004; 9: 291–296.PubMedGoogle Scholar
  45. 45.
    Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG: Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20: 223–231.PubMedGoogle Scholar
  46. 46.
    Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS: Impact of baseline viral load and adherence on survival of HIVinfected adults with baseline CD4 cell counts > or = 200 cells/microl. AIDS 2006; 20: 111711–111723.CrossRefGoogle Scholar
  47. 47.
    Glass TR, De Geest S, Hirschel B, Battegay M, Furrer H, Covassini M, Vernazza PL, Bernasconi E, Rickenboch M, Weber R, Bucher HC, Swiss HIV Cohort Study: Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 2008; 13: 77–85.PubMedGoogle Scholar
  48. 48.
    Zolopa A, Andersen J, Komarow L, Sanchez A, Suckow C, Sanne I, Hogg E, Powderly W, and ACTG A5164 Study Team: Immediate vs deferred ART in the setting of acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG A5164. In: 15th Conference on Retroviruses and Opportunistic Infections. Boston (MA) 3–6 February 2008 (Abstract 142).Google Scholar
  49. 49.
    Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia J: Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis 2003; 37: 1365–1373.PubMedCrossRefGoogle Scholar
  50. 50.
    Antinori A, Larussa D, Cingolani A, Lorenzini P, Bossolasco S, Finazzi MG, Bongiovanni M, Guaraldi G, Grisetti S, Vigo B, Gigli B, Mariano A, Dalle Nogare ER, De Marco M, Moretti F, Corsi P, Abrescia N, Rellecati P, Castagna A, Mussini C, Ammassari A, Cinque P, d’Arminio Monforte A, Italian Registry Investigative NeuroAIDS: Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 1681–1691.PubMedCrossRefGoogle Scholar
  51. 51.
    Morris A, Wachter RM, Luce J, Turner J, Huang L: Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17: 73–80.PubMedCrossRefGoogle Scholar
  52. 52.
    Wislez M, Bergot E, Antoine M, Parrot A, Carette MF, Mayaud C, Cadranel J: Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001; 164: 847–851.PubMedGoogle Scholar
  53. 53.
    Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-Related Malignancies: State of the Art and Therapeutic Challenges. J Clin Oncol 2008; 26: 4834–4842.PubMedCrossRefGoogle Scholar
  54. 54.
    Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, Palmieri F, De Luca A, Larocca LM, Ruco L, Ippolito G, Cauda R: Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15: 1483–1491.PubMedCrossRefGoogle Scholar
  55. 55.
    Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, Stellbrink HJ, Jaeger H, Siebert U, Horst HA: Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17: 1521–1529.PubMedCrossRefGoogle Scholar
  56. 56.
    Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT, Swiss HIV Cohort Study: Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther 2007; 12: 931–939.PubMedGoogle Scholar
  57. 57.
    Cheung MC, Pantanowitz L, Dezube BJ: AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005; 10: 412–426.PubMedCrossRefGoogle Scholar
  58. 58.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A: Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect 2006; 52: 188–194.PubMedCrossRefGoogle Scholar
  59. 59.
    Lawn SD, Myer L, Bekker LG, Wood R: Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335–341.PubMedCrossRefGoogle Scholar
  60. 60.
    Murdoch DM, Venter WD, Feldman C, Van Rie A: Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22: 601–610.PubMedCrossRefGoogle Scholar
  61. 61.
    Mussini C, Pezzotti P, Antinori A, Borghi V, Monforte A, Govoni A, De Luca A, Ammassari A, Mongiardo N, Cerri MC, Bedini A, Beltrami C, Ursitti MA, Bini T, Cossarizza A, Esposito R, Changes in Opportunistic Prophylaxis (CIOP) Study Group: Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis 2003; 36: 645–651.PubMedCrossRefGoogle Scholar
  62. 62.
    Zellweger C, Opravil M, Bernasconi E, Cavassini M, Bucher HC, Schiffer V, Wagels T, Flepp M, Rickenbach M, Furrer H, Swiss HIV Cohort Study: Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study. AIDS 2004; 18: 2047–2053.PubMedCrossRefGoogle Scholar
  63. 63.
    Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit FW, Ledergerber B, Lundgren JD, Furrer H, European HIV Cohorts: Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137: 239–250.PubMedGoogle Scholar
  64. 64.
    Miro JM, Lopez JC, Podzamczer D, Pena JM, Alberdi JC, Martinez E, Domingo P, Cosin J, Claramonte X, Arribas JR, Santin M, Ribera E, GESIDA 04/98 Study Group: Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis 2006; 43: 79–89.PubMedCrossRefGoogle Scholar
  65. 65.
    Berenguer J, Gonzalez J, Pulido F, Padilla B, Casado JL, Rubio R, Arribas JR, Madrid Group for the Study of Discontinuation of Secondary Prophylaxis in Patients with CMV Retinitis: Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 394–397.PubMedCrossRefGoogle Scholar
  66. 66.
    Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, Ingsathit A: Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003; 36: 1329–1331.PubMedCrossRefGoogle Scholar
  67. 67.
    McArthur JC, McDermott MP, McClernon D, St Hillaire C, Conant K, Marder K, Schifitto G, Selnes OA, Sacktor N, Stern Y, Albert SM, Kieburtz K, de Marcaida JA, Cohen B, Epstein LG: Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004; 61: 1687–1696.PubMedCrossRefGoogle Scholar
  68. 68.
    Tozzi V, Balestra P, Galgani S, Narciso P, Sampaolesi A, Antinori A, Giulianelli M, Serraino D, Ippolito G: Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acquir Immune Defic Syndr 2001; 28: 19–27.PubMedGoogle Scholar
  69. 69.
    Parsons TD, Tucker KA, Hall CD, Robertson WT, Eron JJ, Fried MW, Robertson KR: Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS 2006; 20: 1591–1595.PubMedCrossRefGoogle Scholar
  70. 70.
    Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Vigano P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort naïve for Antiretrovirals Study Group: Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naïve HIVinfected individuals. Clin Infect Dis 2005; 40: e101–e109.PubMedCrossRefGoogle Scholar
  71. 71.
    Schifitto G, Kieburtz K, McDermott MP, McArthur J, Marder K, Sacktor N, Palumbo D, Selnes O, Stern Y, Epstein L, Albert S: Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology 2001; 56: 415–418.PubMedGoogle Scholar
  72. 72.
    Marra CM, Lockhart D, Zunt JR, Perrin M, Coombs RW, Collier AC: Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003; 60: 1388–1390.PubMedGoogle Scholar
  73. 73.
    Capparelli EV, Holland D, Okamoto C, Gragg B, Durelle J, Marquie-Beck J, van den Brande G, Ellis R, Letendre S, HNRC Group: Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 2005; 19: 949–952.PubMedCrossRefGoogle Scholar
  74. 74.
    Antinori A, Perno CF, Giancola ML, Forbici F, Ippolito G, Hoetelmans RM, Piscitelli SC: Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41: 1787–1793.PubMedCrossRefGoogle Scholar
  75. 75.
    Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, Andrade RJ, Gonzalez-Serrano M, Aguilar J, Aguilar-Guisado M, Navarro JM, Salmeron J, Caballero-Granado FJ, Garcia-Garcia JA; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas; Grupo Andaluz para el Estudio del Higado: HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779–789.PubMedCrossRefGoogle Scholar
  76. 76.
    Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD, EuroSIDA Group: Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593–601.PubMedCrossRefGoogle Scholar
  77. 77.
    Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL: Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19: 585–592.PubMedGoogle Scholar
  78. 78.
    Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF, Lewin SR, Thio CL: The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naïve patients. AIDS. 2008; 22: 947–955.PubMedCrossRefGoogle Scholar
  79. 79.
    Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18: 2277–2284.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • A. Antinori
    • 1
  • A. Ammassari
    • 1
  • C. Torti
    • 2
  • P. Marconi
    • 1
  • M. Andreoni
    • 3
  • G. Angarano
    • 4
  • S. Bonora
    • 5
  • A. Castagna
    • 6
  • R. Cauda
    • 7
  • M. Clerici
    • 8
  • A. d’Arminio Monforte
    • 9
  • A. De Luca
    • 7
  • G. Di Perri
    • 5
  • M. Galli
    • 10
  • E. Girardi
    • 1
  • A. Gori
    • 11
  • A. Lazzarin
    • 6
  • S. Lo Caputo
    • 12
  • F. Mazzotta
    • 12
  • F. Montella
    • 13
  • C. Mussini
    • 14
  • C. F Perno
    • 3
  • M. Puoti
    • 2
  • G. Rizzardini
    • 15
  • S. Rusconi
    • 10
  • V. Vullo
    • 16
  • G. Carosi
    • 2
  1. 1.Istituto Nazionale Malattie Infettive “Lazzaro Spallanzani” IRCCSRomeItaly
  2. 2.Clinica Malattie Infettive e TropicaliUniversità degli StudiBresciaItaly
  3. 3.Università di Roma “Tor Vergata”RomeItaly
  4. 4.Università degli StudiFoggiaItaly
  5. 5.Ospedale Amedeo di SavoiaUniversità degli StudiTurinItaly
  6. 6.Università “Vita e Salute”San RaffaeleMilanItaly
  7. 7.Università Cattolica del Sacro CuoroRomeItaly
  8. 8.Università degli StudiMilanItaly
  9. 9.A.O. San PaoloUniversità degli StudiMilanItaly
  10. 10.Ospedale L. SaccoUniversità degli StudiMilanItaly
  11. 11.Ospedale S. GerardoUniversità Milano-BicoccaMonzaItaly
  12. 12.Ospedale S.M. AnnunziataFlorenceItaly
  13. 13.Ospedale S. Giovanni AddolorataRomeItaly
  14. 14.Policlinico UniversitarioUniversità degli StudiModenaItaly
  15. 15.Ospedale Luigi SaccoMilanItaly
  16. 16.Università “La Sapienza”RomeItaly

Personalised recommendations